Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
|Articles|September 16, 2008
- December31 2004
- Volume 11
- Issue 24
Bonus Time?
Author(s)Michael Sheehan
Advertisement
According to an October 2004 survey of more than 1200 people by American Healthways (www.americanhealthways.com), most consumers believe that bonus/incentive pay for meeting additional goals or doing superior work is a good idea, but they have different ideas as to which professions should be eligible.
Articles in this issue
about 18 years ago
Red vs Blue: Which Side Are You on?about 18 years ago
Use It or Lose Itabout 18 years ago
On the Frugal Sideabout 18 years ago
Check Your Policyabout 18 years ago
PRN: The Roots of Our Prosperityabout 18 years ago
Did You Know?about 18 years ago
Banks: We Hear Youabout 18 years ago
Spitzer's Warsabout 18 years ago
Build Teen Savingsabout 18 years ago
Stop Orders ExplainedAdvertisement
Related to this article
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy
5